Add to ORKGthe aim of the study was the non-inferiority of raltitrexed as compared with standard 5fluorouracil-folinic acid as adjuvant chemotherapy for radically resected colon cancer patients. 993 patinets have been randomized; the enrollement was prematurely closed when 17 raltitrexed-related deaths were recorded. The toxicity was higher in patinets treated with raltitrexed. RSF and OAS were slight inferion in patinets treated with raltitrexed. In conclusion, the study failed to demonstrate the non-inferiority of raltitrexed
BACKGROUND: The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluoro...
Irinotecan and raltitrexed are active agents in advanced colorectal cancer (ACC) and preclinical dat...
Background: To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TO...
the aim of the study was the non-inferiority of raltitrexed as compared with standard 5fluorouracil-...
OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for re...
Background: Severe 5-FU toxicity in adjuvant therapy of colorectal cancer may require change of ther...
Background: In case of contraindication or intolerance to fluoropyrimidines, raltitrexed is a valida...
Raltitrexed (Tomudex), a thymidylate synthase inhibitor, is an alternative to 5-fluorouracil (5-FU)/...
BACKGROUND5-fluorouracil (FU) is commonly used in preoperative chemoradiation in locally advanced re...
Aims To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatm...
Background: There is no standard treatment for patients with colorectal cancer (CRC) progressing aft...
Background: This study evaluated the antitumor efficacy and safety of a novel oxaliplatin/raltitrexe...
Current chemotherapy regimens used in advanced colorectal cancer (ACRC) are similar in terms of effi...
To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TOMOX) as firs...
Aim: The primary aims of this study were activity and toxicity evaluation of a new raltitrexed and o...
BACKGROUND: The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluoro...
Irinotecan and raltitrexed are active agents in advanced colorectal cancer (ACC) and preclinical dat...
Background: To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TO...
the aim of the study was the non-inferiority of raltitrexed as compared with standard 5fluorouracil-...
OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for re...
Background: Severe 5-FU toxicity in adjuvant therapy of colorectal cancer may require change of ther...
Background: In case of contraindication or intolerance to fluoropyrimidines, raltitrexed is a valida...
Raltitrexed (Tomudex), a thymidylate synthase inhibitor, is an alternative to 5-fluorouracil (5-FU)/...
BACKGROUND5-fluorouracil (FU) is commonly used in preoperative chemoradiation in locally advanced re...
Aims To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatm...
Background: There is no standard treatment for patients with colorectal cancer (CRC) progressing aft...
Background: This study evaluated the antitumor efficacy and safety of a novel oxaliplatin/raltitrexe...
Current chemotherapy regimens used in advanced colorectal cancer (ACRC) are similar in terms of effi...
To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TOMOX) as firs...
Aim: The primary aims of this study were activity and toxicity evaluation of a new raltitrexed and o...
BACKGROUND: The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluoro...
Irinotecan and raltitrexed are active agents in advanced colorectal cancer (ACC) and preclinical dat...
Background: To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TO...